Quick Answer
Jade Biosciences, Inc. reported Operating Income of -$113.54 million for fiscal year 2025.
Jade Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$113.54M | -52.2% |
| 2024 | -$74.60M | +8.4% |
| 2023 | -$81.41M | -52.9% |
| 2022 | -$53.24M | -131.2% |
| 2021 | -$23.02M | -159.0% |
| 2020 | -$8.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$27.40M | -83.1% | +1.4% |
| June 30, 2025 | -$27.78M | -4608.1% | -720.1% |
| March 31, 2025 | -$3.39M | +86.2% | +77.4% |
| September 30, 2024 | -$14.96M | +30.0% | -2436.4% |
| June 30, 2024 | -$590.0K | +97.1% | +97.6% |
| March 31, 2024 | -$24.62M | -39.6% | -15.2% |
| September 30, 2023 | -$21.37M | -51.0% | -5.1% |
| June 30, 2023 | -$20.34M | -66.5% | -15.3% |
- Jade Biosciences, Inc. showed a decrease of -52.2% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Jade Biosciences, Inc.’s operating income has declined by 1177.3% (from -$8.89 million to -$113.54 million).
- The most recent figure is from Jade Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: